Ribociclib-Induced Radiation Recall Dermatitis Following Stereotactic Body Radiation Therapy

Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature

“…There were also two radiation recall cases reported by Erjan et al [ 23 ] and David et al [ 26 ]. In the first case, a grade 2 chest wall dermatitis developed four weeks after radiation therapy, while David et al [ 26 ] reported a case of grade 5 pneumonitis resulting in patient death after palbociclib administration.…”

“…Based on the analysis of the 19 selected articles, 373 patients who received radiotherapy combined with CDK4/6 inhibitors were evaluated across 9 retrospective studies [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ], 4 case reports [ 22 , 23 , 24 , 25 ], 3 case series [ 26 , 27 , 28 ], and 3 letters to the editor [ 29 , 30 , 31 ], as shown in Table 1 .…”

“…There were 10 publications [ 17 , 18 , 19 , 22 , 24 , 25 , 26 , 28 , 29 , 30 ] describing patients who received exclusively palbociclib and 7 publications [ 13 , 14 , 15 , 16 , 20 , 21 , 31 ] that included the three drugs, but of these; palbociclib was also the most prevalent administered drug. In exceptions to this, Meattini [ 27 ] and Erjan [ 23 ] presented data on patients who received only ribociclib, with the first describing five cases and the second reporting a case.…”

“…Based on the analysis of the 19 selected articles, 373 patients who received radiotherapy combined with CDK4/6 inhibitors were evaluated across 9 retrospective studies [13][14][15][16][17][18][19][20][21], 4 case reports [22][23][24][25], 3 case series [26][27][28], and 3 letters to the editor [29][30][31], as shown in Table 1. Data on each study were gathered as follows: name of the principal author, year of publication, study design, number of patients available for analysis, median age at RT treatment, number of RT courses, RT technique, RT dose/fractionation, RT target, CDK4/6 inhibitor used, hormonal therapy given at the time of RT, timing of RT in relation to CDK4/6i, toxicities, and individual patient data when available.…”

“…Based on the analysis of the 19 selected articles, 373 patients who received radiotherapy combined with CDK4/6 inhibitors were evaluated across 9 retrospective studies [13][14][15][16][17][18][19][20][21], 4 case reports [22][23][24][25], 3 case series [26][27][28], and 3 letters to the editor [29][30][31], as shown in Table 1. Ribociclib ( 8) Fulvestrant/ leuprolide (28) Bone-other (61) IMRT ( 18)…”